Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer
about
Anti-RANKL therapy for bone tumours: Basic, pre-clinical and clinical evidencesBone targeted therapies for the prevention of skeletal morbidity in men with prostate cancerRecognizing and treating secondary osteoporosisFuture of bisphosphonates and denosumab for men with advanced prostate cancer.Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomesMedication-induced osteoporosis: screening and treatment strategiesCurrent treatments and novel therapeutic targets for castration resistant prostate cancer with bone metastasisBiochemical markers of bone turnover and clinical outcomes in men with prostate cancerRANKL-Targeted Therapies: The Next Frontier in the Treatment of Male Osteoporosis.An update on the changing indications for androgen deprivation therapy for prostate cancer.Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab.Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancerBone-targeted agents: preventing skeletal complications in prostate cancer.Bone metastases: molecular mechanisms and novel therapeutic interventions.Novel targeted agents on the horizon for castration-resistant prostate cancer.Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.Optimal management of cancer treatment-induced bone loss: considerations for elderly patients.Denosumab and the current status of bone-modifying drugs in breast cancer.Denosumab for the management of bone disease in patients with solid tumors.New developments in the treatment of osteoporosis.Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.A new antiresorptive approach to the treatment of fragility fractures: long-term efficacy and safety of denosumab.Novel bone-targeting agents in prostate cancer.Bone health care for patients with prostate cancer receiving androgen deprivation therapy.Managing bone metastases and reducing skeletal related events in prostate cancer.Contemporary pharmacotherapy for the prevention of skeletal complications in patients with prostate cancer.Antiresorptive therapy in the management of cancer treatment-induced bone loss.Systemic therapy for the treatment of hormone-sensitive metastatic prostate cancer: from intermittent androgen deprivation therapy to chemotherapy.Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs.Local delivery of recombinant osteoprotegerin enhances postorthodontic tooth stability.Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.Prostate cancer and osteoporosis.Palliative Oncology: Denosumab.Cancer Treatment and Bone Health.Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose denosumab in healthy Chinese volunteers: A randomized, single-blind, placebo-controlled study.
P2860
Q26863493-4369D332-EC88-4BA1-8E5B-3C375FDF670DQ27021268-6A25F374-9D91-47EE-9AC8-FF60CFFC721AQ28270738-D9D28075-B9AB-42B2-BF29-2A2A234B7836Q33583525-DA2CB528-6885-4C07-BFCF-6C3A2401E084Q33890406-5D7253C7-527B-423B-8347-512F55228564Q34389358-05D552E3-A9AC-4FC4-9364-1D8277547167Q34448130-ADEBC9AB-8685-4EC1-9D65-EAF8A621C109Q35022212-747B02ED-4526-4DAA-989A-2FD2C34E4834Q35380592-2CD29BD1-5001-4F5D-BCA5-C93B66DE221EQ35549863-C282471B-4BA9-4359-B30C-208DBB7F5A81Q36187103-2D94B645-F8AC-4F47-A855-04AEFCC1C363Q36900805-8A30ECBD-045D-4F51-B465-E4479C5E3018Q37039594-F9478F72-5780-47FA-A120-7CE42BDE1BE0Q37785505-E8FC33AA-B315-4ABB-ADAA-763C4E855531Q37818294-EF6D25E4-421C-469D-B8F7-E4D587C78B9DQ37926896-8C128C98-FB87-49E4-BB89-E4B59D2806B4Q37952851-4550A792-4657-4D14-94CF-C4996D0A8AE8Q37965768-FB5EAC88-98A0-4134-9093-8B7BAE26DFCBQ37970800-FDEC88DF-7CCB-45EA-AAF5-F305E3D62C9CQ38014515-45F7F7B1-D903-4C08-87B5-5820DA543FDAQ38016531-8233ED21-7133-466D-A14D-0EF080EF7102Q38040123-B3A9C47C-962A-4D0F-91DA-FBDC83FD0EC1Q38138862-2FFF02EA-1E6E-40DF-9F6F-EE613B46E943Q38198934-D30B2848-3FF6-4476-9E2A-97AB123D5721Q38207463-29A20903-44E3-4B7A-A03C-CE71C114348CQ38211359-6D0E90C0-82FB-46B2-904A-CD21D5CD7EEBQ38252425-EBECACB7-D908-48DA-B0B1-12FBD01759F8Q38313112-65D6B0FB-EDEB-442D-994A-2DD572561744Q38353828-1A9A7B19-BBEC-4508-B0A1-1AAFB3D3A83BQ38364462-11D07EB4-7040-43CE-87F4-D187E27F7249Q38425187-A1051F3C-C764-417C-B029-5DA30C7CA260Q38803264-8DE5B142-74BF-4F73-B734-E8493F044C09Q45760007-7D5041F7-A10B-4F7A-8A8F-3979C064EE19Q48073269-64E4812D-E109-498B-9410-F2F428C11495Q49211720-3C18D22E-C188-4E93-A127-FD39AF953AD6Q55498037-7CD11F13-1DBD-4EA9-92F7-C0EAD1C40FAE
P2860
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Effects of denosumab on bone m ...... on therapy for prostate cancer
@ast
Effects of denosumab on bone m ...... on therapy for prostate cancer
@en
type
label
Effects of denosumab on bone m ...... on therapy for prostate cancer
@ast
Effects of denosumab on bone m ...... on therapy for prostate cancer
@en
prefLabel
Effects of denosumab on bone m ...... on therapy for prostate cancer
@ast
Effects of denosumab on bone m ...... on therapy for prostate cancer
@en
P2093
P2860
P1476
Effects of denosumab on bone m ...... on therapy for prostate cancer
@en
P2093
Benjamin Z Leder
Blair Egerdie
Carsten Goessl
Chunlei Ke
Maciej Szwedowski
Matthew R Smith
Teuvo L J Tammela
P2860
P304
P356
10.1016/J.JURO.2009.08.048
P407
P577
2009-12-01T00:00:00Z